Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
20 April 2025
| Name: | AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED (API) |
| ISIN: | AU000000API4 |
| Date of Listing: | 16 June 1997 |
| Date of Delisting: | 01 April 2022 |
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 01 April 2022.Legal Status:
ACN: 000 004 320ABN: 57 000 004 320
Registration Date: 19 April 1910
Capital Gains Tax (CGT) Status:
To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. You will need to seek independent tax advice in relation to Capital Gains Tax or other tax matters but any other enquiries relating to your shareholding in the company should be followed up via our online form here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
REGISTRY:
Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail
delisted at entity's request under Listing Rule 17.11 | 01/04/2022 |
we understand WFM Investments Pty Ltd, a wholly-owned subsidiary of Wesfarmers, has acquired 100 per cent of the shares in API for the total consideration of $1.55 cash per share, which included a special dividend of 5 cents paid on 29 March 2022 | 01/04/2022 |
Wesfarmers Limited today announced the implementation of the Scheme of Arrangement under which WFM Investments Pty Ltd, a wholly-owned subsidiary of Wesfarmers, has acquired 100 per cent of the shares in Australian Pharmaceutical Industries Limited. | 31/03/2022 |
The company confirms that the scheme of arrangement, under which WFM Investments Pty Ltd, a wholly owned subsidiary of Wesfarmers Limited, is to acquire 100% of the shares in API that it does not already own, was implemented today. WFM Investments Pty Ltd has now acquired all the issued shares in API. The Special Dividend was paid on 29 March 2022 to API shareholders in respect of API shares held as at 7.00pm (Melbourne time) on Friday, 25 March 2022 and the balance of the Scheme consideration was paid today to all API shareholders in respect of API shares held as at 7.00pm (Melbourne time) on Tuesday, 29 March 2022. | 31/03/2022 |
The company releases a notification of cessation of securities. | 29/03/2022 |
The company releases a letter to its shareholders regarding the special dividend payment. The API Board s pleased to confirm the payment of the fully franked Special Dividend of 3.0c per API Share. | 29/03/2022 |
The securities of Australian Pharmaceutical Industries Limited will be suspended from quotation at the close of trading on Tuesday, 22 March 2022 under Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with ASIC approving the scheme of arrangement by which WFM Investments Pty Ltd, a wholly owned subsidiary of Wesfarmers Limited, will acquire all of the issued shares in API. | 22/03/2022 |
API has today announced that in preparation for the release of its half year results, it will incur an asset impairment charge of $131 million. Notwithstanding this non-cash charge, the underlying business performance is strong, with a net profit after tax of $16.2 million, subject to final auditor review, for the six months ended 28 February 2014 (up from $12.6 million for the prior comparable period). | 17/04/2014 |
The suspension of trading in the securities of Australian Pharmaceutical Industries Limited (the "Company") will be lifted immediately, following the Company's announcement in relation to the carrying value of its assets. Security Code: API | 17/04/2014 |
The securities of Australian Pharmaceutical Industries Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding the carrying value of its assets. Security Code: API | 16/04/2014 |
shares reinstated to quotation | 22/08/2006 |
company advises that the Australian Securities & Investments Commission (ASIC) had granted the company an extension to lodge its Final Accounts on Monday 21 August 2006 - the Australian Stock Exchange (ASX) has advised that API shares will recommence trading the day following the Final Accounts being lodged with ASIC and the ASX | 18/08/2006 |
appoints new CEO, releases preliminary final report and Results for Year Ended 30 April 2006 and also a FY06 Results Presentation - the company has lost $17m but can't explain how or where | 14/08/2006 |
company advises that on Monday 14 August 2006 it will be releasing its full-year financial results for the year ended 30 April 2006. There will be a teleconference briefing held at 1 p.m. on 14 August. The teleconference can be accessed by calling: Dial in # 1800 097 137 Confirmation Code 5065872 | 11/08/2006 |
company advises that the Australian Securities & Investments Commission has granted the company an extension to enable the company to lodge its financial results and report for financial year 2006 on or by 14 August 2006 | 28/07/2006 |
the company today advised that while it had made progress on resolving a number of the issues delaying the release of its financial results, there are still some outstanding items that require further attention | 21/07/2006 |
shares suspended from quotation pending release of an announcement | 14/07/2006 |
delisted at entity's request under Listing Rule 17.11 | 01/04/2022 |
we understand WFM Investments Pty Ltd, a wholly-owned subsidiary of Wesfarmers, has acquired 100 per cent of the shares in API for the total consideration of $1.55 cash per share, which included a special dividend of 5 cents paid on 29 March 2022 | 01/04/2022 |
Wesfarmers Limited today announced the implementation of the Scheme of Arrangement under which WFM Investments Pty Ltd, a wholly-owned subsidiary of Wesfarmers, has acquired 100 per cent of the shares in Australian Pharmaceutical Industries Limited. | 31/03/2022 |
The company confirms that the scheme of arrangement, under which WFM Investments Pty Ltd, a wholly owned subsidiary of Wesfarmers Limited, is to acquire 100% of the shares in API that it does not already own, was implemented today. WFM Investments Pty Ltd has now acquired all the issued shares in API. The Special Dividend was paid on 29 March 2022 to API shareholders in respect of API shares held as at 7.00pm (Melbourne time) on Friday, 25 March 2022 and the balance of the Scheme consideration was paid today to all API shareholders in respect of API shares held as at 7.00pm (Melbourne time) on Tuesday, 29 March 2022. | 31/03/2022 |
The company releases a notification of cessation of securities. | 29/03/2022 |
The company releases a letter to its shareholders regarding the special dividend payment. The API Board s pleased to confirm the payment of the fully franked Special Dividend of 3.0c per API Share. | 29/03/2022 |
The securities of Australian Pharmaceutical Industries Limited will be suspended from quotation at the close of trading on Tuesday, 22 March 2022 under Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with ASIC approving the scheme of arrangement by which WFM Investments Pty Ltd, a wholly owned subsidiary of Wesfarmers Limited, will acquire all of the issued shares in API. | 22/03/2022 |
API has today announced that in preparation for the release of its half year results, it will incur an asset impairment charge of $131 million. Notwithstanding this non-cash charge, the underlying business performance is strong, with a net profit after tax of $16.2 million, subject to final auditor review, for the six months ended 28 February 2014 (up from $12.6 million for the prior comparable period). | 17/04/2014 |
The suspension of trading in the securities of Australian Pharmaceutical Industries Limited (the "Company") will be lifted immediately, following the Company's announcement in relation to the carrying value of its assets. Security Code: API | 17/04/2014 |
The securities of Australian Pharmaceutical Industries Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding the carrying value of its assets. Security Code: API | 16/04/2014 |
shares reinstated to quotation | 22/08/2006 |
company advises that the Australian Securities & Investments Commission (ASIC) had granted the company an extension to lodge its Final Accounts on Monday 21 August 2006 - the Australian Stock Exchange (ASX) has advised that API shares will recommence trading the day following the Final Accounts being lodged with ASIC and the ASX | 18/08/2006 |
appoints new CEO, releases preliminary final report and Results for Year Ended 30 April 2006 and also a FY06 Results Presentation - the company has lost $17m but can't explain how or where | 14/08/2006 |
company advises that on Monday 14 August 2006 it will be releasing its full-year financial results for the year ended 30 April 2006. There will be a teleconference briefing held at 1 p.m. on 14 August. The teleconference can be accessed by calling: Dial in # 1800 097 137 Confirmation Code 5065872 | 11/08/2006 |
company advises that the Australian Securities & Investments Commission has granted the company an extension to enable the company to lodge its financial results and report for financial year 2006 on or by 14 August 2006 | 28/07/2006 |
the company today advised that while it had made progress on resolving a number of the issues delaying the release of its financial results, there are still some outstanding items that require further attention | 21/07/2006 |
shares suspended from quotation pending release of an announcement | 14/07/2006 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 14/12/2020 | Jennifer MacDonald | 25,000 | $1.305 | $32,625 | |
| 24/04/2020 | Mark Smith | 40,000 | $1.039 | $41,550 | |
| 23/04/2020 | Jennifer MacDonald | 15,000 | $1.010 | $15,150 | |
| 03/02/2020 | Mark Smith | 30,000 | $1.299 | $38,981 | |
| 20/12/2019 | Mark Smith | 40,000 | $1.320 | $52,800 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Richard Vincent | Managing Director, CEO | 15/02/2017 |
| Peter Sanguinetti | General Counsel | 30/11/2007 |
| Anne Mustow | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Kenneth Gunderson-Briggs | Chairman, Independent Director | 06/05/2014 | 31/03/2022 |
| Janine Allis | Independent Director | 23/10/2020 | 31/03/2022 |
| Lee Ausburn | Independent Director | 07/10/2008 | 31/03/2022 |
| Clive Stiff | Independent Director | 04/12/2020 | 31/03/2022 |
| Jennifer MacDonald | Non Exec Director | 09/11/2017 | 31/03/2022 |
| George Tambassis | Non Exec Director | 07/06/2021 | 31/03/2022 |
| Mark Smith | Non Exec Chairman, Independent Director | 06/09/2017 | 04/09/2020 |
| Robert Millner | Non Exec Director | 12/05/2000 | 09/07/2020 |
| Gerard Masters | Independent Director | 07/09/2010 | 22/01/2020 |
| Peter Robinson | Non Exec Chairman | 05/05/2000 | 24/01/2018 |
| Stephen Roche | Managing Director, CEO | 14/08/2006 | 15/02/2017 |
| Carol Holley | Independent Director | 19/12/2006 | 25/01/2017 |
| Michael Wooldridge | Independent Director | 01/02/2006 | 31/12/2014 |
| Graeme Fallet | CFO | 24/08/2009 | 19/12/2014 |
| Miles Hampton | Independent Director | 07/08/2007 | 30/01/2014 |
| Barry Frost | Deputy Chairman | 20/09/1993 | 31/07/2008 |
| David Fairfull | Non Exec Director | 05/05/2000 | 16/08/2007 |
| John Murphy | Non Exec Director | 07/10/2004 | 07/08/2007 |
| Gregory Roberston | Alternate Director | 07/10/2004 | 07/08/2007 |
| Michael Smith | Non Exec Director | 25/09/1981 | 21/08/2006 |
| Jeffrey Sher | Executive | 07/10/2004 | 14/08/2006 |
| Graeme Herring | Non Exec Director | 01/04/1997 | 08/06/2004 |
| Fritz Horlacher | Non Exec Director | 21/04/2004 | |
| Peter Wright | Non Exec Director | 21/04/2004 | |
| David Young | Managing Director | 15/11/2000 | 08/01/2004 |
| Frank Conroy | Chairman | 29/10/1999 | 08/07/2003 |
| Verilyn Fitzgerald | Non Exec Director | 01/09/1997 | 08/07/2003 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
